SkyePharma shares lost almost a third of their value on Tuesday after the drug-delivery specialist failed to renegotiate the terms of convertible bonds that mature next year.

The company has convertible bonds with a face value of £89.6m, of which £69.6m could be called for repayment in May 2009. A similar put option exists on another £20m of convertible bonds for June 2010.